Page 2046 - Williams Hematology ( PDFDrive )

2020 Part XII: Hemostasis and Thrombosis Chapter 117: Thrombocytopenia 2021

190. Mikhael J, Northridge K, Lindquist K, et al: Short-term and long-term failure of laparo- 222. Mahevas M, Patin P, Huetz F: B cell deletion in immuno thrombocytopenia reveals
scopic splenectomy in adult immune thrombocytopenic purpura patients: A systematic splenic long-lived plasma cells. J Clin Invest 123:432–442, 2013.
review. Am J Hematol 84:743–748, 2009. 223. Tsutsumi Y, Yamamoto Y, Shimono J, et al: Hepatitis B virus reactivation with rituxi-
191. Ghanima W, Godeau B, Cines DB, Bussel JB: How I treat immune thrombocytopenia: mab-containing regimen. World J Hepatol 5:612–620, 2013.
The choice between splenectomy or a medical therapy as a second-line treatment. Blood 224. Siegal D, Crowther M, Cuker A: Thrombopoietin receptor agonists in primary ITP.
120:960–969, 2012. Semin Hematol 50:S21, 2013.
192. Najean Y, Rain JD, Billotey C: The site of destruction of autologous 111In-labelled plate- 225. Kuter DJ: The biology of thrombopoietin and thrombopoietin receptor agonists. Int J
lets and the efficiency of splenectomy in children and adults with idiopathic throm- Hematol 98:10–23, 2013.
bocytopenic purpura: A study of 578 patients with 268 splenectomies. Br J Haematol 226. Kuter DJ, Bussel JB, Newland AC: Long-term treatment with romiplostim in patients
97:547–550, 1997. with chronic immuno thrombocytopenia: Safety and efficacy. Br J Haematol 161:
193. Pizzuto J, Ambriz R: Therapeutic experience on 934 adults with idiopathic thrombo- 411–423, 2013.
cytopenic purpura: Multicentric Trial of the Cooperative Latin American group on 227. Erhardt JA, Erickson-Miller CL, Aivado M, et al: Comparative analyses of the small
Hemostasis and Thrombosis. Blood 64:1179–1183, 1984. molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in
194. Dolan JP, Sheppard BC, DeLoughery TG: Splenectomy for immune thrombocytopenic vitro platelet function. Exp Hematol 37:1030–1037, 2009.
purpura: Surgery for the 21st century. Am J Hematol 83:93–96, 2007. 228. Tomiyama Y, Miyakawa Y, Okamoto S: A lower dose of eltrombopag is efficacious
195. Lortan JE: Management of asplenic patients. Br J Haematol 84:566–569, 1993. in Japanese patients with previously treated chronic immune thrombocytopenia. J
196. Atkinson WL, Pickering LK, Schwartz B, et al: General recommendations on immu- Thromb Haemost 10:799–806, 2012.
nization. Recommendations of the Advisory Committee on Immunization Practices 229. Saleh MN, Bussel JB, Cheng G: Safety and efficacy of eltrombopag for the treatment
(ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm of chronic immuno thrombocytopenia: Result of the long-term, open label EXTEND
Rep 51:1–35, 2002. study. Blood 121:537–545, 2013.
197. Boyle S, White RH, Brunson A, Wun T: Splenectomy and the incidence of venous 230. Bussel JB, Saleh MN, Vasey SY, et al: Repeated short-term use of eltrombopag in patients
thromboembolism and sepsis in patients with immune thrombocytopenia. Blood with chronic immune thrombocytopenia (ITP). Br J Haematol 160:538–546, 2013.
121:4782–4790, 2015. 231. Columbyova L, Loda M, Scadden DT: Thrombopoietin receptor expression in human
198. Naouri A, Feghali B, Chabal J: Results for splenectomy for idiopathic thrombocy- cancer cell lines and primary tissues. Cancer Res 55:3509–3512, 1995.
topenic purpura. Acta Haematol 89:200–203, 1993. 232. Giagounidis A, Mufti GJ, Fenaux P: Results of a randomized, double-blind study of
199. Newland AC, Treleaven JG, Minchinton RM, Waters AH: High-dose intravenous IgG romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic
in adults with autoimmune thrombocytopenia. Lancet 15:84–87, 1983. syndrome and thrombocytopenia. Cancer 120:1835–1846, 2014.
200. Berchtold P, Dale GL, Tani P, McMillan R: Inhibition of autoantibody binding to plate- 233. Quiquandon I, Fenaux P, Caulier MT, et al: Re-evaluation of the role of azathioprine in
let glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. the treatment of adult chronic idiopathic thrombocytopenic purpura: A report on 53
Blood 74:2414–2417, 1989. cases. Br J Haematol 74:223–228, 1990.
201. Ramamurthi A, Lewis RS: Design of a novel apparatus to study nitric oxide (NO) inhi- 234. Blanchette V, Freedman J, Garvey B: Management of chronic immune thrombocy-
bition of platelet adhesion. Ann Biomed Eng 26:1036–1043, 1998. topenic purpura in children and adults. Semin Hematol 35:36–51, 1998.
202. Imbach P: 30 Years of immunomodulation by intravenous immunoglobulin. Immuno- 235. Verlin M, Laros RK Jr, Penner JA: Treatment of refractory thrombocytopenic purpura
therapy 4:651–654, 2015. with cyclophosphamine. Am J Hematol 1:97–104, 1976.
203. Bussel JB, Pham LC, Aledort L, Nachman R: Maintenance treatment of adults with 236. Reiner A, Gernsheimer T, Slichter SJ: Pulse cyclophosphamide therapy for refractory
chronic refractory immune thrombocytopenic purpura using repeated intravenous autoimmune thrombocytopenic purpura. Blood 85:351–358, 1995.
infusions of gammaglobulin. Blood 72:121–127, 1988. 237. Emillia G, Morselli M, Luppi M: Long-term salvage therapy with cyclosporine A in
204. Hong F, Ruiz R, Price H, et al: Safety profile of WinRho anti-D. Semin Hematol 35:9–13, refractory idiopathic thrombocytopenic purpura. Blood 99:1482–1485, 2002.
1998. 238. Patel AP, Patil AS: Dapsone for immune thrombocytopenic purpura in children and
205. Ware RE, Zimmerman SA: Anti-D: Mechanisms of action. Semin Hematol 35:14–22, 1998. adults. Platelets 26:164–167, 2015.
206. Crow AR, Lazarus AH: The mechanisms of action of intravenous immunoglobulin and 239. Zaja F, Marin L, Chiozzotto M, et al: Dapsone salvage therapy for adults with immune
polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic thrombocytopenia relapsed or refractory to steroid and rituximab. Am J Hematol
purpura: What do we really know? Transfus Med Rev 22:103–116, 2008. 87:321–323, 2012.
207. Despotovic J, Lambert MP, Herman J: RhIg for the treatment of immuno thrombocy- 240. Ahn YS, Byrnes JJ, Harrington WJ, et al: The treatment of idiopathic thrombocytopenia
topenia: Consensus and controversy. Transfusion 52:1126–1136, 2012. with vinblastine-loaded platelets. N Engl J Med 298:1101–1107, 1978.
208. Scaradavou A, Woo B, Woloski BM, et al: Intravenous anti-D treatment of immune 241. Jackson CW, Edwards CC: Evidence that stimulation of megakaryocytopoiesis by low
thrombocytopenic purpura: Experience in 272 patients. Blood 89:2689–2700, 1997. dose vincristine results from an effect on platelets. Br J Haematol 36:97–105, 1977.
209. George JN, Raskob GE, Vesely SK, et al: Initial management of immune thrombo- 242. Tangun Y, Atamer T: More on vincristine in treatment of ITP. N Engl J Med 297:
cytopenic purpura in adults: A randomized controlled trial comparing intermittent 894–895, 1977.
anti-D with routine care. Am J Hematol 74:161–169, 2003. 243. Sekreta CM, Baker DE: Interferon alfa therapy in adults with chronic idiopathic throm-
210. Johnson GJ: Platelet thromboxane receptors: Biology and function, in Handbook of bocytopenic purpura. Ann Pharmacother 30:1176–1179, 1996.
Platelet Physiology and Pharmacology, edited by G Rao, pp 38–79. Kluwer Academic, 244. Snyder HW Jr, Cochran SK, Balint JP Jr, et al: Experience with protein A-immuno-
Boston, 1999. adsorption in treatment-resistant adult immune thrombocytopenic purpura. Blood
211. Waintraub SE, Brody JI: Use of anti-D in immune thrombocytopenic purpura as a 79:2237–2245, 1992.
means to prevent splenectomy: Case reports from two University Hospital Medical 245. Emilia G, Messora C, Longo G, Bertesi M: Long-term salvage treatment by cyclosporin
Centers. Semin Hematol 37:45–49, 2000. in refractory autoimmune haematological disorders. Br J Haematol 93:341–344, 1996.
212. Marcus AJ: Transcellular metabolism of eicosanoids. Prog Hemost Thromb 8:127–142, 246. Strother SV, Zuckerman KS, LoBuglio AF: Colchicine therapy for refractory idiopathic
1986. thrombocytopenic purpura. Arch Intern Med 144:2198–2200, 1984.
213. Narang M, Penner JA, Williams D: Refractory autoimmune thrombocytopenic pur- 247. Bussel JB, Saal S, Gordon B: Combined plasma exchange and intravenous gammaglob-
pura: Responses to treatment with a recombinant antibody to lymphocyte membrane ulin in the treatment of patients with refractory immune thrombocytopenic purpura.
antigen CD20 (rituximab). Am J Hematol 74:263–267, 2003. Transfusion 28:38–41, 1988.
214. Cooper N, Stasi R, Cunningham-Rundles S, et al: The efficacy and safety of B-cell deple- 248. Cines DB, Bussel JB, Liebman HA, Luning Prak ET: The ITP syndrome: Pathogenic and
tion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocy- clinical diversity. Blood 113:6511–6521, 2009.
topenic purpura. Br J Haematol 125:232–239, 2004. 249. Miyakis S, Lockshin MD, Atsumi T, et al: International consensus statement on an
215. Arnold DM, Dentali F, Crowther MA, et al: Systematic review: Efficacy and safety update of the classification criteria for definite antiphospholipid syndrome (APS). J
of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med Thromb Haemost 4:295–306, 2006.
146:25–33, 2007. 250. Cervera R, Piette JC, Font J, et al: Antiphospholipid syndrome: Clinical and immuno-
216. Garvey B: Rituximab in the treatment of autoimmune haematological disorders. Br J logic manifestations and patterns of disease expression in a cohort of 1,000 patients.
Haematol 141:149–169, 2008. Arthritis Rheum 46:1019–1027, 2002.
217. Stasi R: Rituximab in autoimmune hematologic disease: Not just a matter of B cells. 251. Oosting JD, Derksen RH, Bobbink IW, et al: Antiphospholipid antibodies directed
Semin Hematol 47:170–179, 2010. against a combination of phospholipids with prothrombin, protein C, or protein S: An
218. Zaja F, Battista ML, Pirrotta MT: Lower dose rituximab is active in adult patients with explanation for their pathogenic mechanism? Blood 81:2618–2625, 1993.
idiopathic thrombocytopenic purpura. Haematologica 93:930–933, 2008. 252. D’Cruz D, Hughes G: Antibodies, thrombosis and the endothelium. Br J Rheumatol
219. Godeau B: B-cell depletion in immuno thrombocytopenia. Semin Hematol 50:S75–S82, 33:2–4, 1994.
2013. 253. Santoro SA: Antiphospholipid antibodies and thrombotic predisposition: Underlying
220. Hasan A, Michel M, Patel V: Repeated courses of rituximab in chronic ITP: Three dif- pathogenetic mechanisms. Blood 83:2389–2391, 1994.
ferent regimens. Am J Hematol 84:661–665, 2010. 254. Rand JH, Wu XX: Antibody-mediated interference with annexins in the antiphospho-
221. Cooper N, Stasi R, Cunningham-Rundles S: Platelet-associated antibodies, cellular lipid syndrome. Thromb Res 114:383–389, 2004.
immunity and FCGR3a genotype influence the response to rituximab in immune 255. Asherson RA, Khamashta MA, Ordi-Ros J, et al: The “primary” antiphospholipid syn-
thrombocytopenia. Br J Haematol 158:539–547, 2012. drome: Major clinical and serological features. Medicine (Baltimore) 68:366–374, 1989.

Kaushansky_chapter 117_p1993-2024.indd 2021 9/21/15 2:34 PM